MX2023007992A - Compuestos cuadracíclicos fundidos, composiciones y usos de los mismos. - Google Patents
Compuestos cuadracíclicos fundidos, composiciones y usos de los mismos.Info
- Publication number
- MX2023007992A MX2023007992A MX2023007992A MX2023007992A MX2023007992A MX 2023007992 A MX2023007992 A MX 2023007992A MX 2023007992 A MX2023007992 A MX 2023007992A MX 2023007992 A MX2023007992 A MX 2023007992A MX 2023007992 A MX2023007992 A MX 2023007992A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- compositions
- fused quadracyclic
- fused
- quadracyclic compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021071062 | 2021-01-11 | ||
| PCT/US2022/011824 WO2022150707A1 (en) | 2021-01-11 | 2022-01-10 | Fused quadracyclic compounds, compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023007992A true MX2023007992A (es) | 2023-09-27 |
Family
ID=82356986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023007992A MX2023007992A (es) | 2021-01-11 | 2022-01-10 | Compuestos cuadracíclicos fundidos, composiciones y usos de los mismos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240140958A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4274833A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024504927A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230145335A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118574834A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022205678A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023013722A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3204167A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL304142A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023007992A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022150707A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3328394A4 (en) | 2015-07-30 | 2019-03-13 | ModernaTX, Inc. | CONCATEMEE peptide epitope RNAs |
| CN118290358A (zh) * | 2024-03-06 | 2024-07-05 | 江苏医药职业学院 | 一种制备利奈唑胺关键中间体(s)-5-((苄基氨基)甲基)噁唑烷-2-酮的方法 |
| WO2025219950A1 (en) | 2024-04-18 | 2025-10-23 | Astrazeneca Ab | Small molecule cx3cr1 modulators |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10059718B2 (en) * | 2016-01-04 | 2018-08-28 | Tabomedex Biosciences, LLC | Fused quadracyclic compounds, compositions and uses thereof |
-
2022
- 2022-01-10 BR BR112023013722A patent/BR112023013722A2/pt unknown
- 2022-01-10 AU AU2022205678A patent/AU2022205678A1/en active Pending
- 2022-01-10 US US18/270,616 patent/US20240140958A1/en active Pending
- 2022-01-10 JP JP2023541723A patent/JP2024504927A/ja active Pending
- 2022-01-10 CA CA3204167A patent/CA3204167A1/en active Pending
- 2022-01-10 CN CN202280017211.9A patent/CN118574834A/zh active Pending
- 2022-01-10 MX MX2023007992A patent/MX2023007992A/es unknown
- 2022-01-10 WO PCT/US2022/011824 patent/WO2022150707A1/en not_active Ceased
- 2022-01-10 KR KR1020237026555A patent/KR20230145335A/ko active Pending
- 2022-01-10 EP EP22737255.4A patent/EP4274833A4/en active Pending
-
2023
- 2023-06-29 IL IL304142A patent/IL304142A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230145335A (ko) | 2023-10-17 |
| US20240140958A1 (en) | 2024-05-02 |
| IL304142A (en) | 2023-09-01 |
| WO2022150707A1 (en) | 2022-07-14 |
| CN118574834A (zh) | 2024-08-30 |
| AU2022205678A1 (en) | 2023-08-03 |
| EP4274833A4 (en) | 2025-02-19 |
| JP2024504927A (ja) | 2024-02-02 |
| EP4274833A1 (en) | 2023-11-15 |
| CA3204167A1 (en) | 2022-07-14 |
| BR112023013722A2 (pt) | 2024-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021500014A1 (en) | Fused ring compounds | |
| MX2021014441A (es) | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. | |
| PH12021551065A1 (en) | Fused ring compounds | |
| MX2020007797A (es) | Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos. | |
| PH12021553018A1 (en) | New egfr inhibitors | |
| WO2020106647A3 (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| MX2021004245A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. | |
| MX2021002978A (es) | Lactamas biciclicas y metodos de uso de las mismas. | |
| PH12022551522A1 (en) | Smarca degraders and uses thereof | |
| MX2020002183A (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos. | |
| PH12020552154A1 (en) | Compounds | |
| NZ763551A (en) | Compounds useful for inhibiting cdk7 | |
| WO2018195397A3 (en) | Indole ahr inhibitors and uses thereof | |
| ZA202204941B (en) | Cd73 inhibitors | |
| MX2020001793A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos. | |
| MX2025006620A (es) | Compuestos y composiciones como inhibidores de la cinasa c-kit | |
| PH12017502123A1 (en) | Substituted benzamides and methods of use thereof | |
| WO2018183631A8 (en) | Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same | |
| MX2022014007A (es) | Compuestos como inhibidores de bcl-2. | |
| MX2022006776A (es) | Composiciones farmaceuticas oftalmicas. | |
| MX2020012281A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. | |
| PH12021550258A1 (en) | Cdk8/19 inhibitors | |
| BR112023013722A2 (pt) | Compostos quadracílicos fundidos, composições e usos dos mesmos | |
| MX2019005294A (es) | Inhibidores de las interacciones de mtor-deptor y metodos de uso de los mismos. | |
| ZA202100955B (en) | Thrombin inhibitors, formulations, and uses thereof |